TGFB2 and neoplasm: Finally, we show that the early adaptive drug-resistant EGFR-mutant tumor cells under reprogrammed transcriptomic/metabolomics profiles can be secondarily targetable in principle, and are vulnerable to TGFβ2 inhibition, and glutamine-depletion.